Last reviewed · How we verify
Levornidazole Disodium Phosphate for Injection
Levornidazole is a nitroimidazole antimicrobial that generates reactive oxygen species to damage DNA and disrupt cellular function in anaerobic microorganisms and certain parasites.
Levornidazole is a nitroimidazole antibiotic that generates reactive oxygen species and damages microbial DNA, killing anaerobic bacteria and certain parasites. Used for Anaerobic bacterial infections, Trichomoniasis, Amebic dysentery and liver abscess.
At a glance
| Generic name | Levornidazole Disodium Phosphate for Injection |
|---|---|
| Sponsor | Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd |
| Drug class | Nitroimidazole antibiotic |
| Target | Microbial DNA (non-selective; requires anaerobic reduction) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
As the active L-enantiomer of ornidazole, levornidazole penetrates microbial cells and is reduced by anaerobic metabolism to form reactive intermediates that bind to DNA, causing strand breaks and cell death. It is effective against anaerobic bacteria and certain protozoan parasites, particularly Entamoeba histolytica and Trichomonas vaginalis. The disodium phosphate salt formulation enables intravenous administration for systemic infections.
Approved indications
- Anaerobic bacterial infections
- Amebic dysentery and extraintestinal amebiasis
- Trichomoniasis
- Other protozoal and anaerobic infections
Common side effects
- Metallic taste
- Nausea and vomiting
- Headache
- Peripheral neuropathy (with prolonged use)
- Allergic reactions
Key clinical trials
- Pharmacokinetics and Safety Study of Levornidazole Disodium Phosphate for Injection in Subjects With Renal Impairment and Normal Renal Impairment (PHASE1)
- A Study of Levornidazole Disodium Phosphate for Injection vs. Ornidazole in Treatment of Postoperative Intra-Abdominal Infections Caused by Anaerobic Bacteria (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: